Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Pancreatic Neoplasms 8Ovarian Neoplasms 5Mesothelioma, Malignant 4Carcinoma, Non-Small-Cell Lung 4Lung Neoplasms 3Uterine Cervical Neoplasms 2Thyroid Neoplasms 2Stomach Neoplasms 2Neoplasms 2Mesothelioma 2Melanoma 2Glioblastoma 2Uveal Melanoma 1Uterine Neoplasms 1Urinary Bladder Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Phase IB 1Non Hematologic Cancers 1Neoplasms, Mesothelial 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Multiple Myeloma 1Mesonephric Gynecologic Cancer 1Lymphoma 1Low-Grade Serous Ovarian Cancer 1Low Grade Serous Ovarian Cancer 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Hematologic Neoplasms 1

Interventions

Temozolomide 393Radiotherapy 196Bevacizumab 156Radiation 77Magnetic Resonance Spectroscopy 68Lomustine 47Surgical Procedures, Operative 42Carmustine 41pembrolizumab 39Irinotecan 38Nivolumab 32Specimen Handling 27Carboplatin 27Radiosurgery 24Erlotinib Hydrochloride 24Chemotherapy, Adjuvant 23Radiotherapy, Intensity-Modulated 22Drug Therapy 20Cyclophosphamide 20Aminolevulinic Acid 20O(6)-benzylguanine 17sargramostim 16Radiotherapy, Conformal 15temsirolimus 14Granulocyte-Macrophage Colony-Stimulating Factor 14Everolimus 14Vorinostat 13Sorafenib 13poly ICLC 12atezolizumab 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Glioblastoma × defactinib × Clear all
NCT06630260 2026-01-21

5G-RUBY

Institute of Cancer Research, United Kingdom

Phase 1/2 Recruiting
182 enrolled
CNS

Glioblastoma

NCT05798507 2025-12-15

Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With Glioblastoma

Emory University

Phase EARLY_PHASE1 Active not recruiting
14 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡